Company intelligence / Profile preview

Kerastem Technologies, LLC

Solana Beach, California, United Statesbelgraviacentre.com ↗

Ownership: Private
Development stage: Other

Overview

Kerastem’s lead program is an autologous cell-enriched fat grafting procedure for early-stage hair loss. In a Phase II trial (“STYLE”), the therapy showed statistically significant increases in terminal hair counts at 24 weeks versus control. The process involves harvesting a small volume of fat via liposuction, isolating regenerative cells using Celution/Dermapose systems, and injecting enriched adipose tissue into the scalp. The treatment is not FDA-approved or available in the US but has CE mark approval and commercial use in Europe and Japan.

Therapeutic areas: Dermatology
Modalities: Cell therapyBiologicDevice
Industry: Biotech

Partnerships

Cytori Therapeutics (technology licensing)

Beyond the preview

Go deeper on Kerastem Technologies, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kerastem Technologies, LLC.

Explore the full profile